KAYTUS
23.5.2024 09:40:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, launched at ISC High Performance 2024 the K22V2, a multi-node server with exceptional compute density and energy efficiency. The K22V2 integrates two independent hot-swap single-socket compute nodes in a 2U form factor. Each node supports either a 4th Gen AMD EPYC™ 9004 series processor with 12 DDR5 RDIMMs (4800MHz) or a 5th Gen Intel® Xeon® processor with eight DDR5 RDIMMs (5600MHz), offering flexible storage and I/O configurations. Each node also supports 6 SATA/NVMe SSDs or 8 E1.S SSDs, along with 4 PCIe 5.0 slots and one OCP NIC 3.0. This makes it an optimal choice for compute-intensive applications, suitable for customers seeking both high compute density and cooling efficiency.
Advanced 1U Computing Density Enhanced by 2U Cooling and O&M Efficiency
Focused on energy efficiency, K22V2 is fitted to accommodate two single-socket nodes within a 2U space, in a horizontal layout. Each node functions as an autonomous server system, enabling independent hot maintenance with plug-and-play support to minimize disruption, thus significantly enhancing O&M efficiency. This design is advantageous for opting for 2U high efficiency heatsinks. A 2U heatsink, due to its effective utilization of vertical space, features a length merely one-fifth that of a 1U heatsink, facilitating a more efficient server layout. Furthermore, the air flow resistance of a 1U heatsink is four times that of a 2U counterpart at the same air volume (50 CFM), necessitating fans with higher power.
According to testing data, the cooling efficiency of the server in a 2U space is superior when two single-socket nodes are horizontally arranged in parallel compared to when two 1U single-socket nodes are vertically stacked. The K22V2 demonstrates 40% better cooling efficiency compared to two standard 1U rack servers under the same computing conditions, while also reducing power consumption by up to 8%.
New pioneering architecture delivers better cost performance efficiency
The K22V2 server features a streamlined modular design where two nodes share the chassis, backplane, fan, and PSU, providing significant L6 cost advantages compared to products with two independent nodes. This pioneering architecture is optimized for high-performance single-socket processors and addresses the issue of high migration costs associated with a single server failure impacting multiple tasks. Consequently, the K22V2 is versatile, supporting a wide range of typical applications from computing to big data, and is ideal for scenarios requiring demanding computing density and cooling efficiency. Additionally, it offers users more convenient O&M.
System Overview |
KAYTUS K22V2 Multi-node server (Side by side) |
Normal 2x 1U servers (Stack up) |
System Configuration |
||
System depth |
880 mm |
850 mm |
CPU Heatsink |
2U EVAC |
1U EVAC |
Fan |
6056*6 |
4056*8 |
CPU Power (EGS) |
300W |
300W |
CPU Core Count |
104 |
208 |
Thermal Evaluation Result |
||
Fan Duty |
50% |
70% |
Total Fan Power |
83.6W |
268.8W |
Fan Power/Per CPU |
41.8W |
67.2W |
Note |
All thermal evaluations are based on conditions of a 35°C ambient temperature, sea level, and a normally operating fan. |
|
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523837473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom